This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US
by Zacks Equity Research
The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $262.32, moving +0.85% from the previous trading session.
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, Eli Lilly and J&J
by Zacks Equity Research
Pfizer, AbbVie, Eli Lilly and J&J are included in this analyst blog.
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS
by Zacks Equity Research
AbbVie's (ABBV) application seeking approval of Rinvoq for nr-axSpA was based on data from the phase III SELECT-AXIS 2 (Study 2) study.
Lilly (LLY) Inks Deal for Multiple Neurologic Indications
by Zacks Equity Research
Eli Lilly (LLY) partners with Entos Pharmaceuticals to expand its pipeline in multiple neurologic indications.
Pharma Stock Roundup: FDA Nod to PFE Booster for Age 12-15, Breakthrough Tag to ABBV Drug
by Kinjel Shah
FDA authorizes Pfizer's (PFE) booster shot for adolescents 12 -15 years of age and grants Breakthrough Therapy tag to AbbVie's (ABBV) lung cancer candidate.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $271.73, moving -1.63% from the previous trading session.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $276.22 in the latest trading session, marking a -0.37% move from the prior day.
Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung
by Zacks Equity Research
Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $276.43, moving -0.71% from the previous trading session.
Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use
by Zacks Equity Research
Merck's (MRK) oral antiviral molnupiravir secures the FDA-authorized emergency use tag in treating mild-to-moderate COVID-19 in adults for whom other FDA-approved COVID treatments are unsuitable.
Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag
by Zacks Equity Research
Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.
Pfizer (PFE) Gets FDA's Emergency Use Nod for COVID Pill
by Zacks Equity Research
Pfizer's (PFE) COVID-19 pill Paxlovid is the first oral antiviral medicine, which can be prescribed as an at-home treatment for mild-to-moderate COVID-19.
The Zacks Analyst Blog Highlights: Microsoft, Broadcom, Eli Lilly, Intuitive Surgical and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Broadcom, Eli Lilly, Intuitive Surgical and MetLife.
Top Research Reports for Microsoft, Broadcom & Eli Lilly
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Broadcom Inc. (AVGO), and Eli Lilly and Company (LLY).
Lilly's (LLY) Eczema Study on Lebrikizumab Combo Meets Goal
by Zacks Equity Research
Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.
Will Lilly and Pfizer be Top Pharma Stocks Again in 2022?
by Kinjel Shah
Among the large drugmakers, stocks of Pfizer (PFE) and Eli Lilly (LLY) rose significantly in 2021 in response to their pipeline progress.
Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%
by Zacks Equity Research
Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $263.48, moving -1.47% from the previous trading session.
Pharma Stock Roundup: PFE Announces Arena Buyout, LLY Ups 2021 View & More
by Kinjel Shah
Pfizer (PFE) offers to buy Arena Pharmaceuticals. Lilly (LLY) raises 2021 profit and sales outlook.
Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022
by Zacks Equity Research
Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in 2022. It expects to complete the study in four years from the study initiation date.
Eli Lilly (LLY) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?